Henry Scherb
Contact Résumé
02 · Regulatory & Clinical Advocacy
BreakThru SCI · Co-founder, Chief Strategy & Operations Officer · Aug 2025–present

Getting restorative spinal cord injury therapies to patients faster, by bringing the patient voice to Congress, the FDA and the companies building them.

I co-founded BreakThru SCI, a national patient advocacy organization working to speed restorative SCI treatments to patients. We also push for regulatory change, so SCI trials can use designs that fit how the condition actually varies from patient to patient. I lead the organization's strategy and operations, own its partnerships, run fundraising, and built and manage its board.

Why I started BreakThru

When my brother suffered a spinal cord injury, I pledged my life to improving his. In his clinical trial, he and others in his cohort saw real, meaningful changes, but the trial didn't measure them, so they weren't taken seriously. We started advocating right away for regulators to account for the meaningful and variable outcomes SCI trials produce, and that became BreakThru SCI.

13Industry partners across biotech, medtech and brain-computer interfaces
$175KRaised to date; $900K goal by early 2027
20People on the team I help lead
1M+Social media views on clinical trial patient results
8Mainstream news features, including Forbes and Pink Sheet
75+Congressional office meetings since our Capitol Hill briefing

My role

As co-founder, I run BreakThru SCI the way an executive runs a startup: I set strategy, raise the money, build the board and close the partnerships.

Strategy and leadership

Organizational strategy and operations as we scale nationally.

Finance and fundraising

$175K raised toward a $900K goal; donor and investor relations, accounting, compliance and monthly budgets.

Board and governance

Recruited the board co-chairs and members across health policy, regulatory, research, advocacy, nonprofit management and fundraising.

Partnerships and BD

Primary owner of negotiating and executing partnerships with biotech, medtech and BCI companies, advocacy groups and researchers.

Policy and regulatory advocacy

Built and ran our Capitol Hill briefing; support sponsors' FDA discussions from the patient perspective.

Operations and team

Hiring and onboarding, 501(c)(3) filings, internal systems, and our advocacy, social media and PR vendors.

Initiatives

Partnerships and BD

Building a partner ecosystem across the SCI field

Negotiated and executed contracted partnerships across industry, research and policy, including a community sponsorship for Department of Defense research.

Result: 13 industry partners: 6 biotechs, 3 medtech developers and 4 brain-computer interface companies.
Policy and regulatory advocacy

Taking the patient case to Capitol Hill

Built and ran a congressional briefing, addressed congressional and Senate offices, and hosted a panel with Dr. Janet Woodcock, neurotrauma experts and patients.

Result: 75+ follow-up meetings with congressional offices on flexible, patient-relevant SCI trial designs.
Fundraising and donor relations

Raising the capital to scale

Run fundraising and donor and investor relations, including regular donor update calls and written updates.

Result: $175K raised to date, with an active campaign toward $900K by early 2027.
Regulatory strategy

Bringing the patient voice into FDA meetings

We sit in on meetings between the FDA and trial sponsors, helping them design patient-centric trials with relevant endpoints.

Result: Supported a leading SCI trial sponsor that received Breakthrough Therapy Designation.
Governance

Building the board

Recruited the co-chairs and key members covering health policy, regulatory affairs, research, advocacy, nonprofit management and fundraising, and put governance structures in place.

Operations, legal and finance

Standing up the operation

Hiring and onboarding, internal processes and systems, 501(c)(3) filings, donation receipts, accounting, fiscal compliance and monthly budget reports.

Result: A 20-person nonprofit with $175K in 501(c)(3)-compliant donations, and counting.
Communications and media

Building a public platform

Direct our advocacy, social media and PR vendors on initiatives focused on regulatory and policy change.

Result: 1M+ social views on clinical trial patient results and 8 mainstream news features.

Speaking and press

  1. Nov 2026NYBCI26Panel "What Actually Matters to Decision Makers," on a program with Ben Rapoport, Bill Ackman and Neuralink's head of clinical and medical affairs.
  2. Sept 2026Capitol Hill briefingAddressed congressional and Senate offices; hosted a panel with Dr. Janet Woodcock, neurotrauma experts and patients.
  3. Feb 2026U2FP Symposium[Topic or role]
  4. 2027More dates bookedCoverage to date includes Forbes and Pink Sheet.